

## All MCOs: PDL Changes to the Bronchodilators, Beta Agonist Drug Class Effective March 21, 2020

### Background:

HHSC has been informed of possible drug shortages for short-acting agents in the Bronchodilators, Beta Agonist drug class.

### Key Details:

Effective March 21, the following drugs will move from non-preferred to preferred status:

<b>NDC</b>	<b>Drug Name</b>
<b>00093414556</b>	LEVALBUTEROL 0.31 MG/3 ML SOL
<b>00093414656</b>	LEVALBUTEROL 0.63 MG/3 ML SOL
<b>00093414756</b>	LEVALBUTEROL CONC 1.25 MG/0.5
<b>00093414856</b>	LEVALBUTEROL 1.25 MG/3 ML SOL
<b>00115993078</b>	LEVALBUTEROL 0.31 MG/3 ML SOL
<b>00115993178</b>	LEVALBUTEROL 0.63 MG/3 ML SOL
<b>00115993278</b>	LEVALBUTEROL 1.25 MG/3 ML SOL
<b>00378699393</b>	LEVALBUTEROL CONC 1.25 MG/0.5
<b>00378969052</b>	LEVALBUTEROL 0.31 MG/3 ML SOL
<b>00378969152</b>	LEVALBUTEROL 0.63 MG/3 ML SOL
<b>00378969252</b>	LEVALBUTEROL 1.25 MG/3 ML SOL
<b>00591292754</b>	LEVALBUTEROL TAR HFA 45MCG INH
<b>17478017224</b>	XOPENEX 0.31 MG/3 ML SOLUTION
<b>17478017324</b>	XOPENEX 0.63 MG/3 ML SOLUTION
<b>17478017424</b>	XOPENEX 1.25 MG/3 ML SOLUTION
<b>59310058020</b>	PROAIR RESPICLICK 90 MCG INHLR
<b>63402051001</b>	XOPENEX HFA 45 MCG INHALER
<b>65862094324</b>	LEVALBUTEROL 0.31 MG/3 ML SOL
<b>65862094424</b>	LEVALBUTEROL 0.63 MG/3 ML SOL
<b>65862094524</b>	LEVALBUTEROL 1.25 MG/3 ML SOL
<b>66993002127</b>	LEVALBUTEROL 0.31 MG/3 ML SOL

NDC	Drug Name
66993002227	LEVALBUTEROL 0.63 MG/3 ML SOL
66993002327	LEVALBUTEROL 1.25 MG/3 ML SOL
76204070001	LEVALBUTEROL 0.31 MG/3 ML SOL
76204070025	LEVALBUTEROL 0.31 MG/3 ML SOL
76204080001	LEVALBUTEROL 0.63 MG/3 ML SOL
76204080024	LEVALBUTEROL 0.63 MG/3 ML SOL
76204080025	LEVALBUTEROL 0.63 MG/3 ML SOL
76204090001	LEVALBUTEROL 1.25 MG/3 ML SOL
76204090024	LEVALBUTEROL 1.25 MG/3 ML SOL
76204090025	LEVALBUTEROL 1.25 MG/3 ML SOL
00173068220	VENTOLIN HFA 90 MCG INHALER
00254100752	ALBUTEROL HFA 90 MCG INHALER
66993001968	ALBUTEROL HFA 90 MCG INHALER

**Action:**

In accordance with UMCC 8.1.21.14, the MCO must be able to perform off-cycle formulary and PDL updates at HHSC’s request. MCOs must ensure their PBM performs an off-cycle update to reflect these PDL changes in the pharmacy claims processing system as soon as possible.

**Contact:**

For additional information please contact [VDP-Formulary@hhsc.state.tx.us](mailto:VDP-Formulary@hhsc.state.tx.us).